AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-84424893/astrazeneca-returns-compound-rights.html" title="Facts and information about AstraZeneca returns compound rights to Cardiome Pharma.(Brief Article)">AstraZeneca returns compound rights to Cardiome Pharma.(Brief Article)</a>
Close
Set up an RSS feed that alerts you when new articles from M2 Europharma are available.
Frequently asked questions about RSS feeds
AstraZeneca returns compound rights to Cardiome Pharma.(Brief Article)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
The Canadian drug discovery/development company Cardiome Pharma Corp has received notice from the Anglo-Swedish drug manufacturer AstraZeneca Plc that it does not intend to proceed with development of Cardiome's RSD1122 pre-clinical compound.
AstraZeneca plans to return all rights and data associated with the compound to Cardiome. The Canadian …
Related articles from newspapers, magazines, journals, and more
